Billion Dollar Blueprint: The Journey to Blockbuster Status
The industry’s top-selling drugs generate billions in revenues each year. This eBook analyses data on nearly 200 blockbuster drugs, in search of the secret formula for creating the next pharmaceutical behemoth.
Of the 487 drugs approved by the FDA from 2014 to 2023, a staggering 193 are projected to surpass $1 billion in peak-year sales. This suggests nearly 39% of these new drugs are forecast to reach blockbuster status.
The allure of a blockbuster drug lies not only in its ability to generate billions in revenue, bolstering a company’s financial standing, but also in its potential to spur additional investment in R&D initiatives. Success can lead to an enhanced brand image, opening doors to lucrative partnerships and licensing opportunities. No wonder that companies commit so much time and resources into the pursuit of the elusive blockbuster.
In this eBook we use Evaluate data to dive into the dynamics of blockbuster drugs. We survey the existing field of these top-tier products, examine the role that multiple indications play, the time it takes to reach blockbuster status, and consider whether there it is best to develop in-house or seek external assets.
The articles in this eBook originally appeared in Scrip. Find out more here.
